Hemispherx Biopharma to study Alferon against Tamiflu resistant influenza virus strains
It will now be evaluated against wild type and Tamiflu (oseltamivir)-resistant H7N9 influenza virus under the DEA (Data Exchange Agreement) Annex for Medical Preparedness and Bio-Defense Agreement between